Cargando…

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection

(1) Background: Direct-acting antiviral therapy for chronic hepatitis C virus (HCV) infection is associated with high sustained virologic response (SVR) and overcomes negative predictive factors, including steatosis, in patients without human immunodeficiency virus (HIV) coinfection. The impact of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Leigh P., Sterling, Richard K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235799/ https://www.ncbi.nlm.nih.gov/pubmed/32344543 http://dx.doi.org/10.3390/biology9040087

Ejemplares similares

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
por: Martinez, Valrie, et al.
Publicado: (2012)

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
por: Martinez, Valérie, et al.
Publicado: (2013)

Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy
por: Lapa, Daniele, et al.
Publicado: (2021)

24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy
por: Pérez-Is, Laura, et al.
Publicado: (2022)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
por: Cotter, Thomas G., et al.
Publicado: (2021)

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
por: Ghiglione, Yanina, et al.
Publicado: (2020)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
por: Gonzales Zamora, Jose Armando
Publicado: (2018)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
por: Rossi, Carmine, et al.
Publicado: (2019)

Evolution of Pretreatment Assessment and Direct Acting Antiviral Regimens in Accordance with Upgrading Guidelines: A Retrospective Study in HIV/HCV Coinfected Patients †
por: Henry, Zachary, et al.
Publicado: (2018)

Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection
por: Fernandez-Fuertes, M., et al.
Publicado: (2020)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study
por: Machado, Soraia M., et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Prevalence and characteristics of HIV/HBV and HIV/HCV coinfections in Tuscany
por: Puglia, Monia, et al.
Publicado: (2015)

HCV-HIV Chronic Coinfection Prevalence in Amazon Region
por: Lobo, Marcio Nahum, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
por: Vázquez-Morón, Sonia, et al.
Publicado: (2019)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

Sustained Virologic Response with Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis
por: Lebron, Dora, et al.
Publicado: (2017)

Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients
por: Fuster, Daniel, et al.
Publicado: (2021)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
por: Saeed, Sahar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k7dh5sq1vhtr1q16fc9e2jefuk